Back to results
US 12,636,363 B2Granted
Anti-transferrin receptor fusion proteins and methods of use thereof
AssigneeDenali Therapeutics Inc.
InventorsAnnie Arguello, Tina Giese, Gunasekaran Kannan, Mihalis S. Kariolis, Cathal S. Mahon, Junhua Wang
Life of this patent
Estimating the term…
Abstract
Certain embodiments provide a fusion protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence, an IDS variant amino acid sequence, or a catalytically active fragment thereof; and an anti-transferrin receptor (TfR) antibody as described herein, as well as methods of use thereof.
Claims19
A pharmaceutical composition comprising a fusion protein and a pharmaceutically acceptable excipient, wherein the fusion protein comprises:
- (a) two light chain amino acid sequences, each consisting of SEQ ID NO:
- 5;
- (b) a first heavy chain amino acid sequence, a linker, and an iduronate 2-sulfatase (IDS) amino acid sequence, which together consist of SEQ ID NO:17 or SEQ ID NO:
- 18;
- and
- (c) a second heavy chain amino acid sequence, a linker, and an IDS amino acid sequence, which together consist of SEQ ID NO:
- 17 or SEQ ID NO:18;
- and wherein the fusion protein comprises at least about 6 mol/mol sialic acid:fusion protein.
5 more elements
A fusion protein comprising:
- (a) two light chain amino acid sequences, each consisting of SEQ ID NO:
- 5;
- (b) a first heavy chain amino acid sequence, a linker, and an iduronate 2-sulfatase (IDS) amino acid sequence, which together consist of SEQ ID NO:
- 18;
- and
- (c) a second heavy chain amino acid sequence, a linker, and an IDS amino acid sequence, which together consist of SEQ ID NO:
- 18;
- wherein the fusion protein comprises at least about 6 mol/mol sialic acid:fusion protein.
5 more elements
Dependencies are inferred from the claim text.